DE69635088D1 - NEUTROKIN alpha - Google Patents

NEUTROKIN alpha

Info

Publication number: DE69635088D1
Authority: DE; Germany
Prior art keywords: neutrokine alpha; methods; immune system; related disorders; alpha
Prior art date: 1996-10-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69635088T

Other languages

English (en)

Other versions

DE69635088T3 (de

DE69635088T2 (de

Inventor

Guo-Liang Yu

Reinhard Ebner

Jian Ni

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Human Genome Sciences Inc

Original Assignee

Human Genome Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-25

Filing date

1996-10-25

Publication date

2005-09-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22256104&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69635088(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-10-25 Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc

2005-09-22 Application granted granted Critical

2005-09-22 Publication of DE69635088D1 publication Critical patent/DE69635088D1/de

2006-06-14 Publication of DE69635088T2 publication Critical patent/DE69635088T2/de

2012-01-26 Publication of DE69635088T3 publication Critical patent/DE69635088T3/de

2016-10-26 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

230000006303 immediate early viral mRNA transcription Effects 0.000 abstract 2
210000000987 immune system Anatomy 0.000 abstract 2
239000000556 agonist Substances 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
238000002405 diagnostic procedure Methods 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
238000010188 recombinant method Methods 0.000 abstract 1
238000012216 screening Methods 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1
239000013598 vector Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Wood Science & Technology (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Pain & Pain Management (AREA)
Physics & Mathematics (AREA)
Transplantation (AREA)
Rheumatology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Saccharide Compounds (AREA)

DE69635088T 1996-10-25 1996-10-25 NEUTROKIN alpha Expired - Lifetime DE69635088T3 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
PCT/US1996/017957 WO1998018921A1 (en)	1996-10-25	1996-10-25	NEUTROKINE $g(a)
EP96939612A EP0939804B2 (de)	1996-10-25	1996-10-25	NEUTROKIN alpha

Publications (3)

Publication Number	Publication Date
DE69635088D1 true DE69635088D1 (de)	2005-09-22
DE69635088T2 DE69635088T2 (de)	2006-06-14
DE69635088T3 DE69635088T3 (de)	2012-01-26

Family

ID=22256104

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69635088T Expired - Lifetime DE69635088T3 (de)	1996-10-25	1996-10-25	NEUTROKIN alpha

Country Status (14)

Country	Link
EP (3)	EP2230307A1 (de)
JP (1)	JP2001503263A (de)
KR (2)	KR20000052796A (de)
CN (1)	CN1539970A (de)
AT (1)	ATE302272T1 (de)
AU (1)	AU731553B2 (de)
BR (1)	BR9612752A (de)
CA (2)	CA2665133A1 (de)
DE (1)	DE69635088T3 (de)
DK (1)	DK0939804T4 (de)
ES (1)	ES2248823T5 (de)
NZ (1)	NZ334309A (de)
PT (1)	PT939804E (de)
WO (1)	WO1998018921A1 (de)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7597886B2 (en)	1994-11-07	2009-10-06	Human Genome Sciences, Inc.	Tumor necrosis factor-gamma
US7429646B1 (en)	1995-06-05	2008-09-30	Human Genome Sciences, Inc.	Antibodies to human tumor necrosis factor receptor-like 2
US7888466B2 (en)	1996-01-11	2011-02-15	Human Genome Sciences, Inc.	Human G-protein chemokine receptor HSATU68
WO1997033904A1 (en)	1996-03-12	1997-09-18	Human Genome Sciences, Inc.	Death domain containing receptors
US7357927B2 (en)	1996-03-12	2008-04-15	Human Genome Sciences, Inc.	Death domain containing receptors
US6713061B1 (en)	1996-03-12	2004-03-30	Human Genome Sciences, Inc.	Death domain containing receptors
US6635743B1 (en)	1996-03-22	2003-10-21	Human Genome Sciences, Inc.	Apoptosis inducing molecule II and methods of use
US7964190B2 (en)	1996-03-22	2011-06-21	Human Genome Sciences, Inc.	Methods and compositions for decreasing T-cell activity
US8212004B2 (en)	1999-03-02	2012-07-03	Human Genome Sciences, Inc.	Neutrokine-alpha fusion proteins
US6689579B1 (en)	1996-10-25	2004-02-10	Human Genome Sciences, Inc.	Polynucleotides encoding neutrokine-α
US6812327B1 (en)	1996-10-25	2004-11-02	Human Genome Sciences, Inc.	Neutrokine-alpha polypeptides
WO1998027114A2 (en) *	1996-12-17	1998-06-25	Schering Corporation	Mammalian cell surface antigens; related reagents
CA2232743A1 (en) *	1997-04-02	1998-10-02	Smithkline Beecham Corporation	A tnf homologue, tl5
EP1012292A1 (de) *	1997-06-06	2000-06-28	Regeneron Pharmaceuticals, Inc.	Ntn-2, mitglied von tnf-ligand-familie
WO1998055621A1 (en) *	1997-06-06	1998-12-10	Regeneron Pharmaceuticals, Inc.	Ntn-2 member of tnf ligand family
WO1999011791A2 (en) *	1997-09-05	1999-03-11	University Of Washington	Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
IL134480A0 (en) *	1997-09-12	2001-04-30	Apotech Sa	Kay - an immune system protein and dna sequences encoding the same
CA2310987A1 (en) *	1997-11-26	1999-06-03	Eli Lilly And Company	Tnf ligand family gene
US6297367B1 (en) *	1997-12-30	2001-10-02	Chiron Corporation	Polynucleotide encoding TNFL1
AU2093499A (en) *	1997-12-30	1999-07-19	Chiron Corporation	Members of tnf and tnfr families
US7488590B2 (en)	1998-10-23	2009-02-10	Amgen Inc.	Modified peptides as therapeutic agents
GB9828628D0 (en)	1998-12-23	1999-02-17	Glaxo Group Ltd	Novel ligand
ES2338661T3 (es)	1999-01-07	2010-05-11	Zymogenetics, Inc.	Usos terapeuticos de receptores solubles br43x2.
US7833529B1 (en)	1999-01-07	2010-11-16	Zymogenetics, Inc.	Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030095967A1 (en)	1999-01-25	2003-05-22	Mackay Fabienne	BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
WO2000043032A2 (en) *	1999-01-25	2000-07-27	Biogen, Inc.	Baff, inhibitors thereof and their use in the modulation of b-cell response
US6475986B1 (en) *	1999-02-02	2002-11-05	Research Development Foundation	Uses of THANK, a TNF homologue that activates apoptosis
CN100439499C (zh) *	1999-02-23	2008-12-03	人体基因组科学有限公司	Neutrokine-α和Neutrokine-α剪接变体
EP1860190A3 (de) *	1999-02-23	2008-03-12	Human Genome Sciences, Inc.	Neutrokin-alpha und Neutrokin-alpha-Fugenvarianten
CA2363779A1 (en)	1999-02-26	2000-08-31	Human Genome Sciences, Inc.	Human endokine alpha and methods of use
ES2421720T3 (es)	1999-04-12	2013-09-05	Genentech Inc	Homólogos del factor de necrosis tumoral y ácidos nucleicos que los codifican
US20030022233A1 (en) *	1999-04-30	2003-01-30	Raymond G. Goodwin	Methods of use of the taci/taci-l interaction
US6475987B1 (en)	1999-05-06	2002-11-05	National Jewish Medical And Research Center	Tall-1 receptor homologues
CN100526463C (zh)	1999-06-28	2009-08-12	杰南技术公司	利用二价金属离子制备Apo-2配体的方法
BR0013391A (pt)	1999-08-17	2002-07-09	Biogen Inc	Uso do receptor baff (bcma) como um agente imunoregulador
UA74798C2 (uk)	1999-10-06	2006-02-15	Байоджен Айдек Ма Інк.	Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
CA2399387C (en)	2000-02-11	2015-11-03	Biogen, Inc.	Heterologous polypeptide of the tnf family
IL150755A0 (en)	2000-02-16	2003-02-12	Genentech Inc	Uses of agonists and antagonists to modulate activity of tnf-related molecules
US6969519B2 (en)	2000-03-10	2005-11-29	Human Genome Sciences, Inc.	Methods of using an agonistic antibody human tumor necrosis factor receptor (TR17)
KR20020093029A (ko)	2000-04-11	2002-12-12	제넨테크, 인크.	다가 항체 및 그의 용도
JP2003530838A (ja)	2000-04-12	2003-10-21	ヒューマンゲノムサイエンシズインコーポレイテッド	アルブミン融合タンパク質
CA2408617A1 (en)	2000-05-12	2001-11-22	Amgen Inc.	Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
EP2431054A3 (de)	2000-06-15	2013-03-06	Human Genome Sciences, Inc.	Menschlicher Tumornekrosefaktor Delta und Ypsilon
US7220840B2 (en)	2000-06-16	2007-05-22	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator protein
MXPA02012434A (es) *	2000-06-16	2004-09-06	Cambridge Antibody Tech	Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii.
US7879328B2 (en)	2000-06-16	2011-02-01	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator
WO2002009755A2 (en)	2000-07-27	2002-02-07	Genentech, Inc.	Apo-2l receptor agonist and cpt-11 synergism
WO2002018620A2 (en) *	2000-08-15	2002-03-07	Human Genome Sciences, Inc.	Neutrokine-alpha and neutrokine-alpha splice variant
WO2002016411A2 (en)	2000-08-18	2002-02-28	Human Genome Sciences, Inc.	Binding polypeptides and methods based thereon
UA83458C2 (uk)	2000-09-18	2008-07-25	Байоджен Айдек Ма Інк.	Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
WO2002066516A2 (en)	2001-02-20	2002-08-29	Zymogenetics, Inc.	Antibodies that bind both bcma and taci
PL393317A1 (pl)	2001-05-11	2011-05-23	Amgen Inc.	Peptydy oraz pokrewne cząsteczki wiążące TALL-1
DK1436003T3 (da)	2001-05-24	2010-03-15	Zymogenetics Inc	TACI-immunoglobulin-fusionsproteiner
MXPA03010747A (es)	2001-05-25	2004-03-02	Human Genome Sciences Inc	Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
ES2328234T3 (es)	2001-07-03	2009-11-11	Genentech, Inc.	Anticuerpos dr4 humanos y utilizaciones de los mismos.
AR035119A1 (es)	2001-08-16	2004-04-14	Lilly Co Eli	Anticuerpos humanos antagonistas anti-htnfsf13b
US20040186051A1 (en)	2001-10-02	2004-09-23	Kelley Robert F	Apo-2 ligand variants and uses thereof
WO2003033658A2 (en) *	2001-10-17	2003-04-24	Human Genome Sciences, Inc.	Neutrokine-alpha and neutrokine-alpha splice variant
EP2322165A1 (de)	2001-11-13	2011-05-18	Genentech, Inc.	Apo2-Ligand/TRAIL-Formulierungen
US7741285B2 (en)	2001-11-13	2010-06-22	Genentech, Inc.	APO-2 ligand/trail formulations
US7842668B1 (en)	2001-11-13	2010-11-30	Genentech, Inc.	Apo-2 ligand/trail formulations
ES2425738T3 (es)	2001-12-21	2013-10-17	Human Genome Sciences, Inc.	Proteínas de fusión de la albúmina
AU2003247609A1 (en)	2002-06-24	2004-01-06	Genentech, Inc.	Apo-2 ligand/trail variants and uses thereof
AU2003299819A1 (en) *	2002-12-23	2004-07-22	Human Genome Sciences, Inc.	Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof
US7700317B2 (en)	2003-03-28	2010-04-20	Biogen Idec Ma Inc.	Truncated baff receptors
CA2526402A1 (en)	2003-06-05	2005-01-20	Genentech, Inc.	Blys antagonists and uses thereof
US20050255560A1 (en) *	2003-11-21	2005-11-17	Zeren Gao	Ztnf11, a tumor necrosis factor
JP2008505607A (ja) *	2004-01-29	2008-02-28	ジェネンテック・インコーポレーテッド	Ｂｃｍａの細胞外ドメインの変異体とその使用法
WO2006002472A1 (en)	2004-07-02	2006-01-12	Bio-Layer Pty Ltd	Use of metal complexes
JP5237638B2 (ja)	2004-08-06	2013-07-17	ジェネンテック，インコーポレイテッド	バイオマーカーを用いたアッセイおよび方法
EP1774037B1 (de)	2004-08-06	2011-05-11	Genentech, Inc.	Assays und verfahren unter verwendung von biomarkern
US7846662B2 (en)	2004-09-15	2010-12-07	Kowa Company, Ltd.	Method of screening Baff suppressor or inhibitor
KR20070100228A (ko)	2004-10-05	2007-10-10	제넨테크, 인크.	혈관염의 치료 방법
CA2583900A1 (en) *	2004-10-13	2006-04-27	The Washington University	Use of baff to treat sepsis
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
JP2008525002A (ja)	2004-12-23	2008-07-17	ラボラトワールセローノソシエテアノニム	Ｂｃｍａポリペプチド及びその使用
US8029783B2 (en)	2005-02-02	2011-10-04	Genentech, Inc.	DR5 antibodies and articles of manufacture containing same
CN101262876A (zh)	2005-08-09	2008-09-10	酶遗传学股份有限公司	用taci-ig融合分子治疗b细胞恶性肿瘤的方法
CA2618763A1 (en)	2005-08-09	2007-02-15	Zymogenetics, Inc.	Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
PT1915626E (pt)	2005-08-16	2012-02-03	Genentech Inc	Sensibilidade da apoptose a apo2l/trail por ensaio de expressão de galnac-t14 em células/tecidos
US9168286B2 (en)	2005-10-13	2015-10-27	Human Genome Sciences, Inc.	Methods and compositions for use in treatment of patients with autoantibody positive disease
EP3037544A1 (de)	2005-10-13	2016-06-29	Human Genome Sciences, Inc.	Verfahren und zusammensetzung zur verwendung bei der behandlung von systemisch lupus erythematosus patienten mit autoantikörper-positiven leiden
MY149159A (en)	2005-11-15	2013-07-31	Hoffmann La Roche	Method for treating joint damage
AU2006318539B2 (en)	2005-11-23	2012-09-13	Genentech, Inc.	Methods and compositions related to B cell assays
WO2007123765A2 (en)	2006-03-31	2007-11-01	Human Genome Sciences Inc.	Neutrokine-alpha and neutrokine-alpha splice variant
KR20090016707A (ko)	2006-05-15	2009-02-17	아레스 트레이딩 에스.에이.	Ｔａｃｉｉｇ 융합 분자를 사용하여 자가면역 질병을 치료하는 방법
CN105624193B (zh)	2008-09-26	2021-07-13	索元生物医药(美国)有限公司	重组载体
AU2009319864A1 (en)	2008-11-25	2011-07-14	Biogen Idec Ma Inc.	Use of DR6 and P75 antagonists to promote survival of cells of the nervous system
WO2010075249A2 (en)	2008-12-22	2010-07-01	Genentech, Inc.	A method for treating rheumatoid arthritis with b-cell antagonists
US8728730B2 (en)	2009-09-03	2014-05-20	Genentech, Inc.	Methods for treating, diagnosing, and monitoring rheumatoid arthritis
AU2011329647B2 (en)	2010-11-19	2015-10-22	Eisai R&D Management Co., Ltd.	Neutralizing anti-CCL20 antibodies
JP6271254B2 (ja)	2011-02-28	2018-01-31	ジェネンテック，インコーポレイテッド	Ｂ細胞アンタゴニストに対する生物学的マーカー及び応答を予測するための方法
JP2015506950A (ja)	2012-01-31	2015-03-05	ジェネンテック，インコーポレイテッド	抗ｉｇ−ｅｍ１’抗体およびそれを用いる方法
CN103421113B (zh) *	2012-05-22	2018-01-19	武汉华鑫康源生物医药有限公司	抗BLyS抗体
EP3623478A1 (de)	2012-10-25	2020-03-18	Tocagen Inc.	Retroviraler vektor mit mini-promoter-kassette
US9458246B2 (en)	2013-03-13	2016-10-04	Amgen Inc.	Proteins specific for BAFF and B7RP1
PH12022550138A1 (en)	2013-03-13	2023-03-06	Amgen Inc	Proteins specific for baff and b7rp1 and uses thereof
DE102014018663A1 (de)	2014-12-13	2015-03-05	Heinz Kiefer	Nachweis von vermehrungsfähigen Zellen zur Überprüfung von Arzneimittel-Wirkstoffangaben bei Zulassungsverfahren
AR104368A1 (es)	2015-04-03	2017-07-19	Lilly Co Eli	Anticuerpos biespecíficos anti-cd20- / anti-baff
IL297980A (en)	2020-05-08	2023-01-01	Alpine Immune Sciences Inc	Immunomodulatory proteins that inhibit april and baff and methods of using them
CA3216795A1 (en)	2021-05-07	2022-11-10	Alpine Immune Sciences, Inc.	Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
CN113238061B (zh) *	2021-07-09	2021-10-01	中南大学湘雅医院	以cd180阴性b细胞指示重症肌无力病情的试剂盒及应用
KR20250099778A (ko)	2022-10-04	2025-07-02	알파인 이뮨 사이언시즈, 인코포레이티드	자가항체-매개 질환의 치료에 사용하기 위한 돌연변이된 taci-fc 융합 단백질
CN119799684A (zh) *	2024-12-27	2025-04-11	深圳先进技术研究院	一种靶向无害梭菌的抗菌蛋白及其制备方法与应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4263428A (en)	1978-03-24	1981-04-21	The Regents Of The University Of California	Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
EP0052322B1 (de)	1980-11-10	1985-03-27	Gersonde, Klaus, Prof. Dr.	Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
US4433092A (en)	1981-03-09	1984-02-21	Champion Spark Plug Company	Green ceramic of lead-free glass, conductive carbon, silicone resin and AlPO4, useful, after firing, as an electrical resistor
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja)	1982-01-06	1983-07-13	Nec Corp	デ−タ処理装置
DE3374837D1 (en)	1982-02-17	1988-01-21	Ciba Geigy Ag	Lipids in the aqueous phase
DE3218121A1 (de)	1982-05-14	1983-11-17	Leskovar, Peter, Dr.-Ing., 8000 München	Arzneimittel zur tumorbehandlung
EP0102324A3 (de)	1982-07-29	1984-11-07	Ciba-Geigy Ag	Lipide und Tenside in wässriger Phase
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
ATE59966T1 (de)	1983-09-26	1991-02-15	Ehrenfeld Udo	Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
US4615885A (en)	1983-11-01	1986-10-07	Terumo Kabushiki Kaisha	Pharmaceutical composition containing urokinase
DE3586772T2 (de)	1984-07-24	1993-03-04	Coselco Mimotopes Pty Ltd	Verfahren zur bestimmung von mimotopen.
JPS6147500A (ja)	1984-08-15	1986-03-07	Res Dev Corp Of Japan	キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de)	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
US4631211A (en)	1985-03-25	1986-12-23	Scripps Clinic & Research Foundation	Means for sequential solid phase organic synthesis and methods using the same
WO1987001130A1 (en)	1985-08-15	1987-02-26	Stauffer Chemical Company	Tryptophan producing microorganism
ATE114673T1 (de)	1985-08-16	1994-12-15	Univ Rockefeller	Modulator der anabolischen aktivität und seine verwendungen.
US4870163A (en)	1985-08-29	1989-09-26	New York Blood Center, Inc.	Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
EP0247091B1 (de)	1985-11-01	1993-09-29	Xoma Corporation	Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung
DE3888224T2 (de)	1987-04-24	1994-07-21	Teijin Ltd	Bestimmung vom Tumornekrosefaktor; monoklonaler Antikörper und Zusammensetzung.
EP0394827A1 (de)	1989-04-26	1990-10-31	F. Hoffmann-La Roche Ag	Chimärische CD4-Immunoglobulin-Polypeptide
DK0835939T3 (da)	1990-06-28	2006-03-13	Sanofi Aventis Deutschland	Fusionsproteiner med andele af immunglobulin, deres fremstilling og anvendelse
US5480971A (en)	1993-06-17	1996-01-02	Houghten Pharmaceuticals, Inc.	Peralkylated oligopeptide mixtures

1996
- 1996-10-25 DE DE69635088T patent/DE69635088T3/de not_active Expired - Lifetime
- 1996-10-25 ES ES96939612T patent/ES2248823T5/es not_active Expired - Lifetime
- 1996-10-25 EP EP10156941A patent/EP2230307A1/de not_active Withdrawn
- 1996-10-25 CA CA002665133A patent/CA2665133A1/en not_active Abandoned
- 1996-10-25 JP JP52041198A patent/JP2001503263A/ja not_active Withdrawn
- 1996-10-25 NZ NZ334309A patent/NZ334309A/en not_active IP Right Cessation
- 1996-10-25 WO PCT/US1996/017957 patent/WO1998018921A1/en active IP Right Grant
- 1996-10-25 AU AU76745/96A patent/AU731553B2/en not_active Expired
- 1996-10-25 KR KR1019990703614A patent/KR20000052796A/ko not_active Ceased
- 1996-10-25 AT AT96939612T patent/ATE302272T1/de active
- 1996-10-25 PT PT96939612T patent/PT939804E/pt unknown
- 1996-10-25 BR BR9612752-0A patent/BR9612752A/pt not_active Application Discontinuation
- 1996-10-25 EP EP05012261A patent/EP1577391A1/de not_active Withdrawn
- 1996-10-25 CN CNA2004100055320A patent/CN1539970A/zh active Pending
- 1996-10-25 DK DK96939612.6T patent/DK0939804T4/da active
- 1996-10-25 CA CA002266439A patent/CA2266439C/en not_active Expired - Lifetime
- 1996-10-25 EP EP96939612A patent/EP0939804B2/de not_active Expired - Lifetime
- 1996-10-25 KR KR10-2004-7019418A patent/KR20050004269A/ko not_active Ceased

Also Published As

Publication number	Publication date
KR20050004269A (ko)	2005-01-12
WO1998018921A1 (en)	1998-05-07
NZ334309A (en)	2000-08-25
BR9612752A (pt)	2000-01-18
DE69635088T3 (de)	2012-01-26
DE69635088T2 (de)	2006-06-14
AU731553B2 (en)	2001-04-05
EP0939804A1 (de)	1999-09-08
AU7674596A (en)	1998-05-22
KR20000052796A (ko)	2000-08-25
ES2248823T5 (es)	2011-11-03
CN1539970A (zh)	2004-10-27
CA2665133A1 (en)	1998-05-07
ES2248823T3 (es)	2006-03-16
JP2001503263A (ja)	2001-03-13
CA2266439A1 (en)	1998-05-07
EP0939804B1 (de)	2005-08-17
EP0939804B2 (de)	2011-06-15
DK0939804T3 (da)	2005-12-19
DK0939804T4 (da)	2011-07-18
EP1577391A1 (de)	2005-09-21
ATE302272T1 (de)	2005-09-15
EP2230307A1 (de)	2010-09-22
CA2266439C (en)	2009-06-16
PT939804E (pt)	2005-11-30

Legal Events

Date

Code

Title

Description

2006-08-03

8363

Opposition against the patent

2011-07-14

R102

Epo decision maintaining patent in amended form now final

Ref document number: 939804

Country of ref document: EP

Effective date: 20110615

Publication	Publication Date	Title
ATE302272T1 (de)	2005-09-15	Neutrokin alpha
ATE365796T1 (de)	2007-07-15	Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
DE69841140D1 (de)	2009-10-22	Interleukin-17 rezeptor-ähnliches protein
WO1998031806A3 (en)	1998-11-12	Fc receptors and polypeptides
WO1998033920A3 (en)	1998-11-05	Tissue factor pathway inhibitor-3
NZ510367A (en)	2002-11-26	Interleukin 17-like receptor protein nucleic acid sequence encoding the interleukin receptor protein and method of expressing protein in recombinant vector
EP1015468A4 (de)	2000-09-06	Follistatin-3
DE69836956D1 (de)	2007-03-15	Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält
AU6250098A (en)	1998-08-18	Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
DE69434926D1 (de)	2007-04-05	Menschlicher gewebsinhibitor von metalloproteinase-4
ATE472599T1 (de)	2010-07-15	Chemokin alpha-5
HK1042498A1 (zh)	2002-08-16	肿瘤坏死因子受体6α及6β
ATE300554T1 (de)	2005-08-15	Bindegewebe-wachstumsfaktor 3.
WO2003027231A3 (en)	2003-10-16	Polynucleotide encoding adapter protein, pmn29
WO2001032128A3 (en)	2001-11-08	Human chemokine beta-13
WO2000039136A3 (en)	2000-11-02	Human brainiac-5
DE60120507D1 (de)	2006-07-20	Menschliches leucinereiche wiederholungen enthaltendes protein, vorwiegend im dünndarm exprimiert, hlrrsi1
WO2003031566A3 (en)	2004-04-22	Keratinocyte derived interferon
WO2002018622A3 (en)	2002-08-29	TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
EP1187842A4 (de)	2004-03-03	Der tr10 rezeptor des menschlichen tumor-nekrose-faktors
EP1712631A3 (de)	2009-01-21	Fc Rezeptoren
MXPA03004334A (es)	2004-05-04	Receptor novedoso acoplado a proteina g humana, hgprbmy11, expresado altamente en corazon y variantes del mismo.
WO2002074959A3 (en)	2003-04-24	Human leucine-rich repeat containing protein expressed predominately in nervous system tissues, hlrrns1
MXPA03005564A (es)	2004-04-20	Nueva proteina que contiene repeticiones ricas en leucina de humano que es expresada predominantemente en medula osea, hlrrbm1.
MX9801603A (es)	1998-08-30	Alteraciones geneticas relacionadas con la enfermedad de alzheimer hereditaria.